| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 72.05 mm | 72.05 mm | 72.05 mm | 72.05 mm | 72.05 mm | 72.05 mm |
| Cash burn (monthly) | 6.96 mm | 1.27 mm | 8.43 mm | 6.35 mm | 7.04 mm | 5.22 mm |
| Cash used (since last report) | 14.47 mm | 2.64 mm | 17.53 mm | 13.21 mm | 14.65 mm | 10.85 mm |
| Cash remaining | 57.59 mm | 69.41 mm | 54.52 mm | 58.84 mm | 57.40 mm | 61.20 mm |
| Runway (months of cash) | 8.3 | 54.6 | 6.5 | 9.3 | 8.1 | 11.7 |
| 13F holders | Current |
|---|---|
| Total holders | 87 |
| Opened positions | 24 |
| Closed positions | 13 |
| Increased positions | 22 |
| Reduced positions | 20 |
| 13F shares | Current |
|---|---|
| Total value | 274.33 bn |
| Total shares | 48.00 mm |
| Total puts | 73.70 k |
| Total calls | 179.50 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 9.90 mm | $18.32 mm |
| Soleus Capital Master Fund | 6.25 mm | $10.88 mm |
| Qiming U.S. Healthcare Fund II | 5.85 mm | $88.50 mm |
| Roche Finance | 4.62 mm | $0.00 |
| Avego Management | 2.84 mm | $0.00 |
| Amplitude Healthcare | 1.50 mm | $4.41 mm |
| Velan Capital Investment Management | 1.43 mm | $26.97 bn |
| Soleus Capital Management | 1.34 mm | $25.27 bn |
| Soleus Private Equity Fund III | 1.34 mm | $29.24 mm |
| CG The Carlyle Group Inc. | 1.07 mm | $19.90 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Feb 25 | Herb Cross | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 6.2 | 50,000 | 310.00 k | 50,000 |
| 13 Feb 25 | Tucker Edwin Jonathan | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 6.2 | 50,000 | 310.00 k | 50,000 |
| 13 Feb 25 | Jeetinder Singh Mahal | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 6.2 | 50,000 | 310.00 k | 50,000 |
| 13 Feb 25 | Martell Ron | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 6.2 | 130,000 | 806.00 k | 130,000 |
| 12 Dec 24 | Jeetinder Singh Mahal | Voting Common Stock | Sell | Dispose S | No | Yes | 22.11 | 900 | 19.90 k | 25,009 |
| 12 Dec 24 | Jeetinder Singh Mahal | Voting Common Stock | Option exercise | Acquire M | No | Yes | 7.1 | 900 | 6.39 k | 25,909 |
| 12 Dec 24 | Jeetinder Singh Mahal | Stock Option Voting Common Stock | Option exercise | Acquire M | No | Yes | 7.1 | 900 | 6.39 k | 13,772 |
